Introduction to RNA Vaccines.
Methods in molecular biology, January 2017
Thomas Kramps, Knut Elbers, Kramps, Thomas, Elbers, Knut
Thomas Kramps, Knut Elbers
RNA vaccines are attractive, because they exhibit characteristics of subunit vaccines and live-attenuated vectors, including flexible production and induction of both humoral and cellular immunity. While human proof-of-concept for RNA vaccines is still pending, the nascent field of RNA therapeutics has already attracted substantial industry and government funding as well as record investments of private venture capital. Most recently, the WHO acknowledged messenger RNA (mRNA) as a new therapeutic class. In this chapter, we briefly review key developments in RNA vaccines and outline the contents of this volume of Methods in Molecular Biology.
|Members of the public||7||100%|
|Readers by professional status||Count||As %|
|Student > Master||24||14%|
|Student > Bachelor||23||14%|
|Student > Ph. D. Student||19||11%|
|Readers by discipline||Count||As %|
|Biochemistry, Genetics and Molecular Biology||42||25%|
|Agricultural and Biological Sciences||16||10%|
|Pharmacology, Toxicology and Pharmaceutical Science||15||9%|
|Medicine and Dentistry||10||6%|
|Immunology and Microbiology||9||5%|